SB, I don't think so. Check out today's IBD. Big (1/4 page) article on A4 is on ALRT. Article entitled "New Gel Offers 'Gentler' Help For Skin Cancer" with header of "Allegan Ligand Retinoid Therapeutics Inc./ San Diego, California" doesn't have anything new, but it extensively discussed Panretin trial halt for KS as well as oral Panretin's complete remissions for APL. APL FDA approval expected for 1999 but, "One of more other indications could be ready in the meantime, Atkins said. Oral Panretin is currentlyin Phase II testing to treat Kaposi's sarcoma; psoriasis; ovarian, breast, and prostate cancers; pediatric cancer; and bronchial metaplasia, a precancerous lind condition."
Artcile does indicate that ALRI is a joint venture between LGND and AGN, but the only symbol in the article is ALRI. However, many investors will figure out that the real upside is with LGND. Look for another gap higher as retail joins the big boys in the party.
Andy is already wine shopping. |
